Immunocore reports Q4 KIMMTRAK, tebentafusp sales of $50M
The Fly

Immunocore reports Q4 KIMMTRAK, tebentafusp sales of $50M

The preliminary unaudited total net product and net pre-product revenue arising from the sales of KIMMTRAK and tebentafusp was ~$50 million in Q4 2022, an increase of ~25% compared to the previous quarter, and ~$140 million for full year 2022. Preliminary unaudited cash and cash equivalents were ~$400 million USD year end 2022. In 2023, the Company will continue to launch in additional countries and establish KIMMTRAK globally as first line treatment for metastatic uveal melanoma, while exploring how to enhance patient convenience. In addition, the Company is enrolling patients into a Phase 2/3 trial to investigate the potential of tebentafusp in advanced cutaneous melanoma.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on IMCR:

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App